Skip to main content

Public access policy to published NIH research moves forward

Below is a press release I just thought might interest some of you that have been following this issue.

Alliance for Taxpayer Access
www.taxpayeraccess.org
For immediate release
October 24, 2007
Contact:Jennifer McLennanjennifer [at] arl [dot] org(202) 296-2296 ext. 121

MANDATE FOR PUBLIC ACCESS TO NIH-FUNDED RESEARCHPOISED TO BECOME LAW
Full U.S. Senate Approves Bill Containing Support for Access ToTaxpayer-Funded Research

Washington, D.C. – October 24, 2007 - The U.S. Senate last night approved the FY2008 Labor, HHS, and Education Appropriations Bill (S.1710), includinga provision that directs the National Institutes of Health (NIH) tostrengthen its Public Access Policy by requiring rather than requestingparticipation by researchers. The bill will now be reconciled with the House Appropriations Bill, which contains a similar provision, in another step toward support for public access to publicly funded research becoming UnitedStates law.

“Last night’s Senate action is a milestone victory for public access totaxpayer-funded research,” said Heather Joseph, Executive Director of SPARC(the Scholarly Publishing and Academic Resources Coalition, a founding member of the ATA). “This policy sets the stage for researchers, patients,and the general public to benefit in new and important ways from ourcollective investment in the critical biomedical research conducted by the NIH.”

Under a mandatory policy, NIH-funded researchers will be required to deposit
copies of eligible manuscripts into the National Library of Medicine’s online database, PubMed Central. Articles will be made publicly available no later than 12 months after publication in a peer-reviewed journal. The current NIH Public Access Policy, first implemented in 2005, is a voluntary measure and has resulted in a deposit rate of less than 5% by individual investigators. The advance to a mandatory policy is the result of more than two years of monitoring and evaluation by the NIH, Congress, and the community.

“We thank our Senators for taking action on this important issue,” said Pat Furlong, Founding President and CEO of Parent Project Muscular Dystrophy.“This level of access to NIH-funded research will impact the disease process in novel ways, improving the ability of scientists to advance therapies and enabling patients and their advocates to participate more effectively. The advance is timely, much-needed, and – we anticipate – an indication of increasingly enhanced access in future.”

“American businesses will benefit tremendously from improved access to NIH research,” said William Kovacs, U.S. Chamber of Commerce vice president for environment, technology and regulatory affairs. “The Chamber encourages the free and timely dissemination of scientific knowledge produced by the NIH as it will improve both the public and industry’s ability to become better informed on developments that impact them – and on opportunities for innovation.” The Chamber is the world’s largest business federation, representing more than three million businesses of every size, sector, and region.

“We welcome the NIH policy being made mandatory and thank Congress for backing this important step,” said Gary Ward, Treasurer of the American Society for Cell Biology (ASCB). “Free and timely public access toscientific literature is necessary to ensure that new discoveries are made as quickly as feasible. It’s the right thing to do, given that tax payers fund this research.” The ASCB represents 11,000 members and publishes thehighly ranked peer-reviewed journal, Molecular Biology of the Cell. Joseph added, “On behalf of the taxpayers, patients, researchers, students, libraries, universities, and businesses that pressed this bill forward with their support over the past two years, the ATA thanks Congress for throwing its weight behind the success of taxpayer access to taxpayer-funded research.” Negotiators from the House and Senate are expected to meet to reconciletheir respective bills this fall. The final, consolidated bill will have to pass the House and the Senate before being delivered to the President at theend of the year.


###

Comments

Popular posts from this blog

Ratner's Cheesecake

Here's another recipe from Toby! Thanks Toby......and I'll get the others posted soon! Ratner's Cheesecake and plain cookies Ratner's was a Jewish dairy restaurant in the lower East Side of Manhattan. This recipe, from my disintegrating, no longer in print Ratner's cookbook, is the closest I've ever gotten to reproducing the rich, heavy cheesecake my mother made when I was a kid. It's worth the time it takes to prepare and every last calorie. Dough Can be prepared in advance. Makes enough for two cakes. Can be frozen or used to make cookies – see recipe below. 1 cup sugar 1 teaspoon vanilla extract 1 cup shortening 1 teaspoon lemon extract 1 cup butter 2 eggs 3 cups sifted cake flour ½ teaspoon salt 2 cups all purpose flour 1 teaspoon baking powder 1. In a bowl, combine all ingredients with hands. Refrigerate 3 -4 hours, or preferably overnight. Filling (for

The next generation with Hermansky-Pudlak Syndrome

I'm so behind on posting about the trip to Puerto Rico. Since the episode of Mystery Diagnosis on Hermansky-Pudlak Syndrome ran right after we got home, it's been a little busy. These, however, are my favorite pictures from Puerto Rico. I know, not pretty senery etc - but these little guys and gals inspire me. They are the next generation of folks with HPS, and if we keep up the hard work, they will live better lives because of it. They motivate me.

Some good news about Pirfenidone

Below is a press release from Intermune, the company that makes Pirfenidone. They have essentially reviewed the various clinical trials going on, and decided that Pirfenidone is safe and well tolerated. That would pretty much go along with what we've observed in the HPS community as well. We have a few folks that have been on the drug since the late 90s and continue to do well. Of course, as a journalist, I do have to say consider the source - but at the same time, as someone in a Pirfenidone trial, it's good to know. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting - Analysis shows safety and tolerability of pirfenidone across four clinical trials - VIENNA, Sept. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria